Author details

Full Name

Stephen D Schmidt

Affiliation

ORCID

Career Start Year

1995

Papers

117

H Index

Expertise

CM4AI Collaborator

PMID	Paper Title	Journal Title	Published Year
36265510	Bivalent SARS-CoV-2 mRNA vaccines increase breadth of neutralization and protect against the BA.5 Omicron variant in mice.	Nat Med	2023
35243372	Protocol to identify and monitor key mutations of broadly neutralizing antibody lineages following sequential immunization of Ig-humanized mice.	STAR Protocols	2022
35447072	mRNA-1273 or mRNA-Omicron boost in vaccinated macaques elicits similar B cell expansion, neutralizing responses, and protection from Omicron.	Cell	2022
36284200	Engineering of HIV-1 neutralizing antibody CAP256V2LS for manufacturability and improved half life.	Scientific Reports	2022
35378757	Primary exposure to SARS-CoV-2 variants elicits convergent epitope specificities, immunoglobulin V gene usage and public B cell clones.	bioRxiv	2022
35547849	Safety and Immunogenicity of a Third Dose of SARS-CoV-2 mRNA Vaccine - An Interim Analysis.		2022
36263060	Bivalent SARS-CoV-2 mRNA vaccines increase breadth of neutralization and protect against the BA.5 Omicron variant.	bioRxiv	2022
36517467	Primary exposure to SARS-CoV-2 variants elicits convergent epitope specificities, immunoglobulin V gene usage and public B cell clones.	Nat Commun	2022
35316213	Binding and neutralizing antibody responses to SARS-CoV-2 in very young children exceed those in adults.	JCI insight	2022
34986348	Potent anti-viral activity of a trispecific HIV neutralizing antibody in SHIV-infected monkeys.	Cell Rep	2022
35081298	SARS-CoV-2 Omicron Variant Neutralization after mRNA-1273 Booster Vaccination.	N Engl J Med	2022
34931200	Booster of mRNA-1273 Strengthens SARS-CoV-2 Omicron Neutralization.	medRxiv	2021
33785631	Functional Anatomy of the Trimer Apex Reveals Key Hydrophobic Constraints That Maintain the HIV-1 Envelope Spike in a Closed State.	mBio	2021
34210892	Ultrapotent antibodies against diverse and highly transmissible SARS-CoV-2 variants.	Science	2021
33453152	Vaccination induces maturation in a mouse model of diverse unmutated VRC01-class precursors to HIV-neutralizing antibodies with >50% breadth.	Immunity	2021
34031659	Durability of mRNA-1273-induced antibodies against SARS-CoV-2 variants.	bioRxiv	2021
33822494	Antibody Persistence through 6 Months after the Second Dose of mRNA-1273 Vaccine for Covid-19.	New England Journal of Medicine	2021
33270381	Durability of Responses after SARS-CoV-2 mRNA-1273 Vaccination.	N Engl J Med	2021
34672695	Protection against SARS-CoV-2 Beta variant in mRNA-1273 vaccine-boosted nonhuman primates.	Science	2021
34426813	Protection against SARS-CoV-2 Beta Variant in mRNA-1273 Boosted Nonhuman Primates.	bioRxiv	2021
32663912	An mRNA Vaccine against SARS-CoV-2 - Preliminary Report.	N Engl J Med	2020
32130953	VRC34-Antibody Lineage Development Reveals How a Required Rare Mutation Shapes the Maturation of a Broad HIV-Neutralizing Lineage.	Cell Host Microbe	2020
31581292	Longitudinal Antibody Responses in People Who Inject Drugs Infected With Similar Human Immunodeficiency Virus Strains.	J Infect Dis	2020
32295908	Development of a 3Mut-Apex-Stabilized Envelope Trimer That Expands HIV-1 Neutralization Breadth When Used To Boost Fusion Peptide-Directed Vaccine-Elicited Responses.	Journal of Virology	2020
32991794	Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults.	N Engl J Med	2020
32756549	SARS-CoV-2 mRNA vaccine design enabled by prototype pathogen preparedness.	Nature	2020
32577634	SARS-CoV-2 mRNA Vaccine Development Enabled by Prototype Pathogen Preparedness.	bioRxiv	2020
32722908	Evaluation of the mRNA-1273 Vaccine against SARS-CoV-2 in Nonhuman Primates.	N Engl J Med	2020
31513771	A Meta-analysis of Passive Immunization Studies Shows that Serum-Neutralizing Antibody Titer Associates with Protection against SHIV Challenge.		2019
31589168	Glycan-dependent HIV-specific neutralizing antibodies bind to cells of uninfected individuals.	Journal of Clinical Investigation	2019
30317905	Limited anti-HIV neutralizing antibody breadth and potency before and after HIV superinfection in Danish men who have sex with men.	Infectious Diseases	2019
31206510	Star nanoparticles delivering HIV-1 peptide minimal immunogens elicit near-native envelope antibody responses in nonhuman primates.	PLoS Biology	2019
30943274	Rational design and in vivo selection of SHIVs encoding transmitted/founder subtype C HIV-1 envelopes.	PLoS Pathog	2019
30995238	Consistent elicitation of cross-clade HIV-neutralizing responses achieved in guinea pigs after fusion peptide priming by repetitive envelope trimer boosting.	PLoS One	2019
29444432	Surface-Matrix Screening Identifies Semi-specific Interactions that Improve Potency of a Near Pan-reactive HIV-1-Neutralizing Antibody.	Cell Rep	2018
30538178	Structural Constraints at the Trimer Apex Stabilize the HIV-1 Envelope in a Closed, Antibody-Protected Conformation.	mBio	2018
28052137	Mapping Polyclonal HIV-1 Antibody Responses via Next-Generation Neutralization Fingerprinting.	PLoS Pathog	2017
28768869	Protective Efficacy of Broadly Neutralizing Antibodies with Incomplete Neutralization Activity against Simian-Human Immunodeficiency Virus in Rhesus Monkeys.	Journal of Virology	2017
28539448	Virological Control by the CD4-Binding Site Antibody N6 in Simian-Human Immunodeficiency Virus-Infected Rhesus Monkeys.	J Virol	2017
28445724	Quantification of the Impact of the HIV-1-Glycan Shield on Antibody Elicitation.	Cell Rep	2017
28931655	Protection against a mixed SHIV challenge by a broadly neutralizing antibody cocktail.	Science Translational Medicine	2017
28931639	Trispecific broadly neutralizing HIV antibodies mediate potent SHIV protection in macaques.	Science	2017
28878010	Broadly neutralizing antibodies targeting the HIV-1 envelope V2 apex confer protection against a clade C SHIV challenge.	Science Translational Medicine	2017
28296911	Longitudinal dynamics of the HIV-specific B cell response during intermittent treatment of primary HIV infection.	PLoS ONE	2017
27581986	Structure of an N276-Dependent HIV-1 Neutralizing Antibody Targeting a Rare V5 Glycan Hole Adjacent to the CD4 Binding Site.	Journal of Virology	2016
27120156	A single injection of anti-HIV-1 antibodies protects against repeated SHIV challenges.	Nature	2016
27610571	Induction of HIV Neutralizing Antibody Lineages in Mice with Diverse Precursor Repertoires.	Cell	2016
26581981	Human Immunodeficiency Virus Type 1 Monoclonal Antibodies Suppress Acute Simian-Human Immunodeficiency Virus Viremia and Limit Seeding of Cell-Associated Viral Reservoirs.	J Virol	2015
25787288	Sustained Delivery of a Broadly Neutralizing Antibody in Nonhuman Primates Confers Long-Term Protection against Simian/Human Immunodeficiency Virus Infection.	Journal of Virology	2015
25858157	Analysis of immunoglobulin transcripts and hypermutation following SHIV(AD8) infection and protein-plus-adjuvant immunization.	Nat Commun	2015